Evidence map›Paper›PMID 41407860›Full record

Trial reportNature2026

Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.

Lixin Guo, Bo Zhang, Xia Xue, Xin Zhang, Hanqing Cai, Hongwei Jiang, Lili Zhang, Ping Jin, Xiaojing Wang, Zhifeng Cheng and 13 more

Registry-linked trialAbstract readRandomized Controlled TrialClinical Trial, Phase IIIComparative Study
PubMed Publisher
In one paragraph

Trial report in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07654062 (Efficacy and Safety of Mazdutide in Adults With Prediabetes), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07654062 phase4not yet recruitingnot on this map

Efficacy and Safety of Mazdutide in Adults With Prediabetes: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial (DREAM-PRE)

TypeinterventionalSponsorShandong Provincial HospitalRan2026 to 2029Enrolled150ConditionsPrediabetes, Impaired Fasting Glucose, Impaired Glucose Tolerance (Prediabetes)ArmsMazdutide, Placebo, Standardized Lifestyle Intervention
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Advancing the Understanding of the Mo-CBPProbiotics and antimicrobial proteins · 2026
    Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Lixin Guo *Department of Endocrinology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Bo Zhang *China-Japan Friendship Hospital, Beijing, China.ORCID 0000-0003-3060-7850
Xia XueCentral Hospital Affiliated to Shandong First Medical University, Jinan, China.
Xin ZhangGenertec Liaoyou Gem Flower Hospital, Panjin, China.
Hanqing CaiSecond Norman Bethune Hospital of Jilin University, Changchun, China.
Hongwei JiangFirst Affiliated Hospital, and College of Clinical Medicine, State Key Laboratory of Light Superalloys, Henan University of Science and Technology, Luoyang, China.
Lili ZhangJincheng General Hospital, Jincheng, China.
Ping JinThird Xiangya Hospital of Central South University, Changsha, China.
Xiaojing WangYuncheng Central Hospital, Yuncheng, China.
Zhifeng ChengFourth Affiliated Hospital of Harbin Medical University, Harbin, China.
Suhe ZhangSecond Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jianlin GengHengshui People's Hospital (Harrison International Peace Hospital), Hengshui, China.
Yushan GuoAffiliated Hospital of Bei-hua University, Jilin, China.
Hanbo HuInnovent Biologics, Suzhou, China.
Qingyang MaInnovent Biologics, Suzhou, China.
Li LiInnovent Biologics, Suzhou, China.
Haiwei DuInnovent Biologics, Suzhou, China.ORCID 0000-0001-6058-267X
Han Han-ZhangInnovent Biologics, Suzhou, China.
Fengtai XueInnovent Biologics, Suzhou, China.
Huan DengInnovent Biologics, Suzhou, China.
Lei QianInnovent Biologics, Suzhou, China.ORCID 0000-0001-8720-7140
Wenying YangChina-Japan Friendship Hospital, Beijing, China. ywying_1010@126.com.
DREAMS-2 investigators

Funding

Innovent Biologics
6 · The paper itself

Abstract

Mazdutide is a once-weekly glucagon and glucagon-like peptide 1 receptor dual agonist developed for the treatment of type 2 diabetes (T2D)

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsAdultAgedAsian PeopleBody WeightChinaEast Asian PeopleFemaleGlucagon-Like Peptide-1 Receptor AgonistsGlycated HemoglobinHumansMaledulaglutideGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsImmunoglobulin Fc FragmentsmazdutidePeptidesRecombinant Fusion Proteins

Identifiers

PMID41407860

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.